VivoSim Labs, Inc. (LON:0R02)
3.174
+0.065 (2.09%)
At close: Mar 20, 2025
VivoSim Labs Revenue
VivoSim Labs had revenue of $37.00K USD in the quarter ending June 30, 2025, a decrease of -5.13%. This brings the company's revenue in the last twelve months to $142.00K, up 94.52% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$142.00K
Revenue Growth
+94.52%
P/S Ratio
43.93
Revenue / Employee
$10.92K
Employees
13
Market Cap
4.55M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
VivoSim Labs News
- 6 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 6 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 7 months ago - Organovo reports $11.3M cash balance in FY24 - Seeking Alpha
- 7 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 7 months ago - Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
- 7 months ago - Organovo Provides Business Update - GlobeNewsWire
- 7 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 7 months ago - Organovo announces reverse stock split; shares fall - Seeking Alpha